Interaction of β1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling

Journal of Clinical Investigation

Volumn 1, Issue 1, 2016, Pages

  Zhu, Weizhong ^a   Tsang, Sharon ^b   Browe, David M ^b   Woo, Anthony Y H ^c,d   Huang, Ying ^c   Xu, Chanjuan ^e   Liu, Jian Feng ^e   Lv, Fengxiang ^c   Zhang, Yan ^c   Xiao, Rui Ping ^c  

^a NANTONG UNIVERSITY   (China)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PEKING UNIVERSITY   (China)

^d SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84994723646     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/jci.insight.84969     Document Type: Article

References (58)

1. Zhu WZ, et al. Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest. 2003;111(5):617-625.
2. Zhu WZ, et al. Activation of CaMKIIδC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. J Biol Chem. 2007;282(14):10833-10839.
3. Du XJ, Cox HS, Dart AM, Esler MD. Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. Cardiovasc Res. 1999;43(4):919-929.
4. Graham LN, Smith PA, Huggett RJ, Stoker JB, Mackintosh AF, Mary DA. Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction. Circulation. 2004;109(19):2285-2289.
5. Zhang W, Huang BS, Leenen FH. Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction. Am J Physiol. 1999;276(5 pt 2):H1608-H1615.
6. Garcia-Egido A, et al. Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. Int J Clin Pract. 2015;69(5):550-559.
7. Braun AP, Schulman H. The multifunctional calcium/calmodulin-dependent protein kinase: from form to function. Annu Rev Physiol. 1995;57:417-445.
8. De Koninck P, Schulman H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science. 1998;279(5348):227-230.
9. Erickson JR, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 2008;133(3):462-474.
10. Mangmool S, Shukla AK, Rockman HA. β-Arrestin-dependent activation of Ca2+/calmodulin kinase II after β1-adrenergic receptor stimulation. J Cell Biol. 2010;189(3):573-587.
11. He BJ, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med. 2011;17(12):1610-1618.
12. Zhang T, et al. The δC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003;92(8):912-919.
13. Sossalla S, et al. Diastolic dysfunction and arrhythmias caused by overexpression of CaMKIIδ(C) can be reversed by inhibition of late Na+ current. Basic Res Cardiol. 2011;106(2):263-272.
14. Joiner ML, et al. CaMKII determines mitochondrial stress responses in heart. Nature. 2012;491(7423):269-273.
15. Hori O, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem. 1995;270(43):25752-25761.
16. Yang Y, et al. Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo. Am J Physiol Heart Circ Physiol. 2006;291(6):H3065-H3075.
17. Bucciarelli LG, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation. 2006;113(9):1226-1234.
18. Vesikansa A, et al. Expression of GluK1c underlies the developmental switch in presynaptic kainate receptor function. Sci Rep. 2012;2:310.
19. Schmidt AM, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest. 1995;96(3):1395-1403.
20. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 2000;275(51):40096-40105.
21. Lazaros G, et al. Distinct association of admission hyperglycemia with one-year adverse outcome in diabetic and non-diabetic patients with acute ST-elevation myocardial infarction. Hellenic J Cardiol. 2013;54(2):119-125.
22. Usami M, et al. Effect of intracoronary thrombectomy on 30-day mortality in non-diabetic patients with acute hyperglycemia after acute myocardial infarction. J Cardiol. 2009;53(3):429-436.
23. Huttunen HJ, Kuja-Panula J, Rauvala H. Receptor for advanced glycation end products (RAGE) signaling induces CREBdependent chromogranin expression during neuronal differentiation. J Biol Chem. 2002;277(41):38635-38646.
24. Liu Y, et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-κB pathways. Atherosclerosis. 2010;208(1):34-42.
25. Zeng S, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology. 2004;39(2):422-432.
26. Muhammad S, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci. 2008;28(46):12023-12031.
27. Di Filippo C, Cuzzocrea S, Rossi F, Marfella R, D'Amico M. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev. 2006;24(2):77-87.
28. Sixt S, et al. Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease. Eur Heart J. 2010;31(1):112-119.
29. Yan SF, et al. RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res. 2004;1(1):10-20.
30. Schalkwijk CG, Baidoshvili A, Stehouwer CD, van Hinsbergh VW, Niessen HW. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta. 2004;1636(2-3):82-89.
31. Buckingham RE, Hanna A. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Diabetes Obes Metab. 2008;10(4):312-328.
32. Ishihara M, et al. Comparison of blood glucose values on admission for acute myocardial infarction in patients with versus without diabetes mellitus. Am J Cardiol. 2009;104(6):769-774.
33. Vlasselaers D, et al. Tight glycemic control protects the myocardium and reduces inflammation in neonatal heart surgery. Ann Thorac Surg. 2010;90(1):22-29.
34. Nakashima A, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(12):2213-2219.
35. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
36. Aleshin A, et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol. 2008;294(4):H1823-H1832.
37. Prasanna X, Chattopadhyay A, Sengupta D. Role of lipid-mediated effects in β2-adrenergic receptor dimerization. Adv Exp Med Biol. 2015;842:247-261.
38. Zhu WZ, et al. Heterodimerization of β1- and β2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ Res. 2005;97(3):244-251.
39. Usami M, et al. Clinical impact of acute hyperglycemia on development of diabetes mellitus in non-diabetic patients with acute myocardial infarction. J Cardiol. 2014;63(4):274-280.
40. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007;9(12):1146-1155.
41. Koyama Y, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail. 2007;13(3):199-206.
42. van Heerebeek L, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117(1):43-51.
43. Hartog JW, et al. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J. 2007;28(23):2879-2885.
44. Volz HC, et al. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol. 2010;105(6):805-820.
45. Peters RW, et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. J Chronic Dis. 1987;40(1):75-82.
46. Hawkins CM, Richardson DW, Vokonas PS. Effect of propranolol in reducing mortality in older myocardial infarction patients. Circulation. 1983;67(6 pt 2):I94-I97.
47. Sawicki PT, Siebenhofer A. Beta-blocker treatment in diabetes mellitus. J Intern Med. 2001;250(1):11-17.
48. Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012;11:14.
49. Ohtsuka T, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37(2):412-417.
50. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem. 2009;16(8):940-952.
51. Lee EJ, Park JH. Receptor for Advanced Glycation Endproducts (RAGE), its ligands, and aoluble RAGE: potential biomarkers for diagnosis and therapeutic targets for human renal diseases. Genomics Inform. 2013;11(4):224-229.
52. Zhang W, Qi F, Chen DQ, Xiao WY, Wang J, Zhu WZ. Ca2+/calmodulin-dependent protein kinase IIδ orchestrates G-protein-coupled receptor and electric field stimulation-induced cardiomyocyte hypertrophy. Clin Exp Pharmacol Physiol. 2010;37(8):795-802.
53. Liao RJ, et al. Rescue of cardiac failing and remodelling by inhibition of protein phosphatase 1gamma is associated with suppression of the alternative splicing factor-mediated splicing of Ca2+/calmodulin-dependent protein kinase δ. Clin Exp Pharmacol Physiol. 2014;41(12):976-985.
54. Singh MV, et al. Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart. J Clin Invest. 2009;119(4):986-996.
55. Erickson JR, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013;502(7471):372-376.
56. Luo M, et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest. 2013; 123(3):1262-1274.
57. Tae HJ, et al. The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth. J Mol Med (Berl). 2013;91(12):1369-1381.
58. Zhou YY, et al. Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. Am J Physiol Heart Circ Physiol. 2000;279(1):H429-H436.